{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-138915","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.991649+00:00","generated_at":"2026-06-15T08:49:34.814034+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration","bullets":["FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.","Therapy targets neoantigens identified via Adaptive's TCR discovery platform.","Genentech responsible for clinical, regulatory, and commercialization efforts.","Adaptive reaffirms FY2023 revenue guidance of $205-215 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-138915","json":"https://secwatch.observer/filing/0001193125-23-138915.json","markdown":"https://secwatch.observer/filing/0001193125-23-138915.md","text":"https://secwatch.observer/filing/0001193125-23-138915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/0001193125-23-138915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000119312523138915/d420874d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:49:34.814034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}